Revelation Biosciences (FRA:56U0) Change In Payables And Accrued Expense : €0.50 Mil (TTM As of Mar. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Revelation Biosciences Change In Payables And Accrued Expense?

Revelation Biosciences's Change In Payables And Accrued Expense for the quarter that ended in Mar. 2024 was €-0.19 Mil. It means Revelation Biosciences's Accounts Payable & Accrued Expense declined by €0.19 Mil from Dec. 2023 to Mar. 2024 .

Revelation Biosciences's Change In Payables And Accrued Expense for the fiscal year that ended in Dec. 2023 was €0.84 Mil. It means Revelation Biosciences's Accounts Payable & Accrued Expense increased by €0.84 Mil from Dec. 2022 to Dec. 2023 .

Revelation Biosciences Change In Payables And Accrued Expense Historical Data

The historical data trend for Revelation Biosciences's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Revelation Biosciences Change In Payables And Accrued Expense Chart

Revelation Biosciences Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Change In Payables And Accrued Expense

0.81

-1.15

0.84

Revelation Biosciences Quarterly Data
	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Payables And Accrued Expense	Get a 7-Day Free Trial								0.16	-0.25	0.81	0.13	-0.19

Revelation Biosciences Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.50 Mil.

Revelation Biosciences Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of Revelation Biosciences's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Revelation Biosciences (FRA:56U0) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Revelation Biosciences Inc (FRA:56U0) » Definitions » Change In Payables And Accrued Expense

Comparable Companies

Traded in Other Exchanges

REVB:USA 56U1:Germany

Address

4660 La Jolla Village Drive, Suite 100, San Diego, CA, USA, 92122

Website

https://www.revbiosciences.com

Revelation Biosciences Inc is a clinical-stage life sciences company focused on the development of immunologic-based therapies for the prevention and treatment of disease. It has several product candidates in development. REVTx-99, the lead therapeutic candidate, is an intranasal immunomodulator to prevent or treat infections caused by various respiratory viruses such as SARS-CoV-2, including its variants, influenza A and B, parainfluenza, rhinovirus, and RSV. REVTx-99 is also being developed for other indications such as: allergic rhinitis and chronic nasal congestion. REVTx-200 is an intranasal immunomodulator adjunct to be used in combination with an intramuscular vaccination for more complete immunity. REVTx-200 is based on the same technology used in REVTx-99.

Revelation Biosciences (FRA:56U0) Headlines

No Headlines